Search This Blog

Wednesday, June 12, 2024

'Two dozen companies working to find bird flu vaccine for cows, US agriculture secretary says'

 Twenty-four companies are working to develop an avian flu vaccine for cattle, as the virus spreads among U.S. dairy herds, Agriculture Secretary Tom Vilsack told Reuters on Wednesday.

Bird flu has infected 90 dairy herds across 12 states since late March, according to the U.S. Department of Agriculture (USDA). Three dairy farm workers also have been infected with the virus, two in Michigan and one in Texas.

A vaccine could curb the risk of bird flu spreading to new species and lessen potential economic losses for dairy farmers, but may take years to develop.

In addition to the two dozen companies working at varying stages of vaccine development, the USDA is conducting its own preliminary research into a vaccine at its laboratory in Ames, Iowa, Vilsack said in an interview.

The agency is looking for a vaccine candidate to test for efficacy, he said.

"That could happen tomorrow, or it could take six months, or it could take a year," Vilsack said.

The agency's other efforts on bird flu include research into potential respiratory spread of the virus between cows and providing support to farmers to increase biosecurity on farms.

While wild birds were a major vector for bringing bird flu to poultry farms, the main risks to spread on dairy farms appear to be the movement of people and equipment, he said.

"For dairy cows, it isn't about migratory birds, it's about cows moving, it's about people, vehicles and equipment that may have virus they don't even realize that they're carrying," he said. "That's why the biosecurity becomes just incredibly, incredibly important."

A pilot program for bulk milk testing will be rolled out "in the very near future," Vilsack said. The program is meant to expand testing for the virus while enabling healthy herds to move across state lines without negative tests from each cow.

Michigan and Idaho are among states that have expressed interest in the program, Vilsack said.

https://www.yahoo.com/news/two-dozen-companies-working-bird-194836617.html

Blinken: 'Hamas proposed numerous changes, some unworkable, to U.S.-backed proposal'

 U.S. Secretary of State Antony Blinken said on Wednesday that Hamas had proposed numerous changes, some unworkable, to a U.S.-backed proposal for a ceasefire with Israel in Gaza, but that mediators were determined to close the gaps.

Senior Hamas official Osama Hamdan denied that the Palestinian Islamist group had put forward new ideas. Speaking to pan-Arab Al-Araby TV, he reiterated Hamas' stance that it was Israel that was rejecting proposals and accused the U.S. administration of going along with its close ally to "evade any commitment" to a blueprint for a permanent ceasefire in Gaza.

White House National Security Adviser Jake Sullivan said on Wednesday many of Hamas' proposed changes were minor "and not unanticipated" while others differed more substantially from what was outlined in a U.N. Security Council resolution on Monday backing the plan put forward by U.S. President Joe Biden.

"Our aim is to bring this process to a conclusion. Our view is that the time for haggling is over," Sullivan told reporters.

Hamas also wants written guarantees from the U.S. on the ceasefire plan, two Egyptian security sources told Reuters.

Earlier on Wednesday, Izzat al-Rishq, from Hamas' political bureau based outside Gaza, said its formal response to the U.S. proposal was "responsible, serious and positive" and "opens up a wide pathway" for an accord.

Biden's proposal envisages a truce and a phased release of Israeli hostages in Gaza in exchange for Palestinians jailed in Israel, ultimately leading to a permanent end to the war.

At a press conference with Qatar's prime minister in Doha, Blinken said some of the counter-proposals from Hamas, which has ruled Gaza since 2007, had sought to amend terms that it had accepted in previous talks.

MONTHS OF TALKS

Negotiators from the U.S., Egypt and Qatar have tried for months to mediate a ceasefire in the conflict - which has killed tens of thousands of Palestinians and devastated the heavily populated enclave - and free the hostages, more than 100 of whom are believed to remain captive in Gaza.

"Hamas could have answered with a single word: Yes," Blinken said. "Instead, Hamas waited nearly two weeks and then proposed more changes, a number of which go beyond positions that it had previously taken and accepted."

The U.S. has said Israel has accepted its proposal, but Israel has not publicly stated this.

Blinken said Washington would in coming weeks float ideas for a post-war Gaza administration and rebuilding of the enclave. "We have to have plans for the day after the conflict ends in Gaza, and we need to have them as soon as possible."

Major powers are intensifying efforts to defuse the conflict in part to prevent it spiralling into a wider Middle East war, with a dangerous flashpoint being the escalating hostilities along the Lebanese-Israeli border.

Lebanon's Hezbollah militia, backed by Iran, fired barrages of rockets at Israel on Wednesday in retaliation for the killing of a senior Hezbollah field commander. Israel said it had in turn attacked the launch sites from the air.

Taleb Abdallah, or Abu Taleb, was the most senior Hezbollah commander killed in the conflict, a security source said, and Hezbollah official Hashem Safieddine vowed that the group would expand its operations against Israel.

UN FINDINGS ON WAR CRIMES

The fighting in Gaza began on Oct. 7 when militants led by Hamas burst across the border and killed 1,200 Israelis and took more than 250 hostage, according to Israeli tallies.

Israel's air and ground war since then has killed more than 37,000 Palestinians, according to Gaza's health ministry, displaced most of Gaza's population of 2.3 million and devastated housing and infrastructure.

The head of the World Health Organization said on Wednesday many people in Gaza were facing "catastrophic hunger and famine-like conditions", with over 8,000 children under five years old diagnosed and treated for acute malnutrition.

A U.N. inquiry found that both Israel and Hamas had committed war crimes early in the Gaza war, and that Israel's actions also constituted crimes against humanity because of the immense civilian losses.

The U.N. Commission of Inquiry (COI) produced two parallel reports, one focusing on the Oct. 7 attacks and another on Israel's response.

Israel, which did not cooperate, dismissed the findings as the result of anti-Israeli bias. Hamas did not immediately comment.

The reports released in Geneva, which cover the period to December, found both sides had committed war crimes including torture; murder or wilful killing; outrages upon personal dignity; and inhuman or cruel treatment.

Evidence gathered by such U.N.-mandated bodies can form the basis for war crimes prosecutions.

It could be drawn on by the International Criminal Court, where prosecutors last month requested arrest warrants for Israeli Prime Minister Benjamin Netanyahu, his defence minister and three Hamas leaders for alleged war crimes.

ISRAEL CONTINUES ASSAULTS IN GAZA

As diplomats sought a ceasefire deal, Israel continued assaults in central and southern Gaza that are among the bloodiest of the war.

Netanyahu has repeatedly said Israel will not commit to end its campaign before Hamas is eliminated.

Residents said Israeli forces had pounded areas across Gaza on Wednesday as tanks advanced towards the northern part of the city of Rafah, which skirts the Egyptian border.

Palestinian health officials said six people had been killed in an airstrike on Gaza City in the north, and one man had been killed by a tank shell in Rafah.

In the central city of Deir Al-Balah, mother-of-two Huda said the displaced had lost hope that the war would end anytime soon. "We lost faith both in our leaders, and in the world," she told Reuters via a chat app.

"Ceasefire promises by our leaders and the world are like words written in butter at night, they disappear with the first light of day."

https://www.yahoo.com/news/hamas-says-creates-broad-prospects-010922090.html

With Bird Flu Tests Hard to Get, How to Know When to Sound Pandemic Alarm?

 Stanford University infectious disease doctor Abraar Karan, MD, MPH, has seen a lot of patients with runny noses, fevers, and irritated eyes lately. Such symptoms could signal allergies, COVID, or a cold. This year, there's another suspect, bird flu -- but there's no way for most doctors to know.

If the government doesn't prepare to ramp up H5N1 bird flu testingopens in a new tab or window, he and other researchers warn, the U.S. could be caught off guard again by a pandemic.

"We're making the same mistakes today that we made with COVID," Deborah Birx, MD, who served as former President Donald Trump's coronavirus response coordinator, said June 4 on CNNopens in a new tab or window.

To become a pandemic, the H5N1 bird flu virus would need to spread from person to personopens in a new tab or window. The best way to keep tabs on that possibility is by testing people.

Scientifically speaking, many diagnostic laboratories could detect the virus. However, red tape, billing issues, and minimal investment are barriers to quickly ramping up widespread availability of testing. At the moment, the FDA has authorized only the CDC's bird flu test, which is used only for people who work closely with livestock.

State and federal authorities have detected bird flu in dairy cattle in 12 states. Three people who work on separate dairy farms tested positive, and it is presumed they caught the virus from cows. Yet researchers agree that number is an undercount given the CDC has tested only about 40 people for the disease.

"It's important to know if this is contained on farms, but we have no information because we aren't looking," said Helen Chu, MD, MPH, an infectious disease specialist at the University of Washington in Seattle who alerted the country to COVID's spread in 2020 by testing people more broadly.

Reports of untested sick farmworkersopens in a new tab or window -- as well as a maternity workeropens in a new tab or window who had flu symptoms -- in the areas with H5N1 outbreaks among cattle in Texas suggest the numbers are higher. And the mild symptoms of those who tested positive -- a cough and eye inflammation, without a fever -- are such that infected people might not bother seeking medical care and, therefore, wouldn't be tested.

The CDC has asked farmworkers with flu symptoms to get tested, but researchers are concerned about a lack of outreachopens in a new tab or window and incentives to encourage testing among people with limited job security and access to healthcare. Further, by testing only on dairy farms, the agency likely would miss evidence of wider spread.

"It's hard to not compare this to COVID, where early on we only tested people who had traveled," said Benjamin Pinsky, MD, PhD, medical director of the clinical virology laboratory at Stanford University. "That left us open to not immediately recognizing that it was transmitting among the community."

In the early months of COVID, the rollout of testing in the U.S. was catastrophically slowopens in a new tab or window. Although the World Health Organization had validated a test and other groups had developed their own using basic molecular biology techniques, the CDC at first insisted on creating and relying on its own testopens in a new tab or window. Adding to delays, the first version it shipped to state health labs didn't work.

The FDA lagged, too. It didn't authorize tests from diagnostic laboratories outside of the CDC until late February 2020.

On Feb. 27, 2020, Chu's research lab detectedopens in a new tab or window COVID in a teenager who didn't meet the CDC's narrow testing criteria. This case sounded an alarm that COVID had spread below the radar. Scaling up to meet demand took time: Months passed before anyone who needed a COVID test could get one.

Chu notes this isn't 2020 -- not by a long shot. Hospitals aren't overflowing with bird flu patients. Also, the country has the tools to do much better this time around, she said, if there's political will.

For starters, tests that detect the broad category of influenza that H5N1 belongs to, called influenza A, are FDA-approved and ubiquitous. These are routinely run in the "flu season," from November to February. An unusual number of positives from these garden-variety flu tests this spring and summer could alert researchers that something is awry.

Doctors, however, are unlikely to request influenza A tests for patients with respiratory symptoms outside of flu season, in part because health insurers may not cover them except in limited circumstances, said Alex Greninger, MD, PhD, MPhil, assistant director of the clinical virology laboratory at the University of Washington.

That's a solvable problem, he added. At the peak of the COVID pandemic, the government overcame billing issues by mandating that insurance companies cover tests, and set a lucrative price to make it worthwhile for manufacturers. "You ran into a testing booth on every other block in Manhattan because companies got $100 every time they stuck a swab in someone's nose," Greninger said.

Another obstacle is that the FDA has yet to allow companies to run their influenza A tests using eye swabs, although the CDC and public health labs are permitted to do so. Notably, the bird flu virus was detected only in an eye swab from one farmworker infected this year -- and not in samples drawn from the nose or throat.

Overcoming such barriers is essential, Chu said, to ramp up influenza A testing in regions with livestock. "The biggest bang for the buck is making sure that these tests are routine at clinics that serve farmworker communities," she said, and suggested pop-up testing at state fairs, too.

In the meantime, novel tests that detect the H5N1 virus, specifically, could be brought up to speed. The CDC's current test isn't very sensitive or simple to use, researchers said.

Stanford, the University of Washington, the Mayo Clinic, and other diagnostic laboratories that serve hospital systems have developed alternatives to detecting the virus circulating now. However, their reach is limited, and researchers stress a need to jump-start additional capacity for testing before a crisis is underway.

"How can we make sure that if this becomes a public health emergency we aren't stuck in the early days of COVID, where things couldn't move quickly?" Pinsky said.

recent ruleopens in a new tab or window that gives the FDA more oversight of lab-developed testsopens in a new tab or window may bog down authorization. In a statement to KFF Health News, the FDA said that, for now, it may allow tests to proceed without a full approval process. The CDC did not respond to requests for comment.

But the American Clinical Laboratory Association has asked the FDA and the CDC for clarity on the new rule. "It's slowing things down because it's adding to the confusion about what is allowable," said Susan Van Meter, president of the diagnostic laboratory trade group.

Labcorp, Quest Diagnostics, and other major testing companies are in the best position to manage a surge in testing demand because they can process hundreds per day, rather than dozens. But that would require adapting testing processes for their specialized equipment, a process that consumes time and money, said Matthew Binnicker, PhD, director of clinical virology at the Mayo Clinic.

"There's only been a handful of H5N1 cases in humans the last few years," he said, "so it's hard for them to invest millions when we don't know the future."

The government could provide funding to underwrite its research, or commit to buying tests in bulk, much as Operation Warp Speed did to advance COVID vaccine development.

"If we need to move to scale this, there would need to be an infusion of money," said Kelly Wroblewski, MPH, director of infectious disease programs at the Association of Public Health Laboratories. Like an insurance policy, the upfront expense would be slight compared with the economic blow of another pandemic.

Other means of tracking the H5N1 virus are critical, too. Detecting antibodies against the bird flu in farmworkers would help reveal whether more people have been infected and recovered. And analyzing wastewateropens in a new tab or window for the virus could indicate an uptick in infections in people, birds, or cattle.

As with all pandemic preparedness efforts, the difficulty lies in stressing the need to act before a crisis strikes, Greninger said.

"We should absolutely get prepared," he said, "but until the government insures some of the risk here, it's hard to make a move in that direction."

https://www.medpagetoday.com/infectiousdisease/surveillance/110587

FDA Warns Company Making Stem Cell Products for Pets

 FDA has sent a warning letter

opens in a new tab or window to a company that makes stem cell and platelet-rich plasma products -- for pets.

The agency told Texas-based Safari Stem Cell that statements on the company's websiteopens in a new tab or window and social media accounts show its products are intended to treat a variety of diseases and conditions in animals, but lack proper approval.

Safari Stem Cell claims its products can treat a range of diseases in pets, including arthritis, kidney disease, dry eye, and intervertebral disc disease, according to the warning letter. Its tissue- and cell-based products are derived from donated tissues from cats and dogs, FDA said.

However, those products should be considered animal drugs, which are subject to FDA regulation. However, the company doesn't have approval for them, nor does it have a "new animal drug application" approved to conduct research, the agency said.

During an inspection, FDA also discovered "significant deviations" from Current Good Manufacturing Practice (CGMP) regulations. These included failing to have written protocols to ensure quality of the products, failing to test for microorganisms, and failing to monitor environmental conditions in an aseptic area, according to the letter.

FDA said the company responded to an earlier notice about these violations in May 2023, which included a statement that it would cease operations. However, the warning letter was issued on April 5, 2024 after the company continued to promote and sell products on its website.

Steven Garner, the president of Safari Stem Cell, told MedPage Today that the company has already made efforts to address the agency's concerns, including building a new CGMP compliant lab and updating the company's standard operating procedures and protocols.

"We were expecting most of the allegations and have addressed them," Garner said in an email. "We have been in operation for over 10 years with no notice from the FDA. We do have significant differences of opinion but are working with consultants on how to move forward."

Garner added that the company's goal is to "treat untreatable fatal diseases of pet animals in our hospital with stem cells," and he believes the company "should be able to continue this practice with proper client consent."

After receiving the FDA warning letter, Garner said the company sent a formal response to the agency. He added that the company is still awaiting a response from the FDA.

"Our initial response was sent within the required time frame and we set timelines for accomplishment of some of the tasks required. We have done these tasks but were awaiting a response from the FDA," he said.

The warning marks the latest efforts from the FDA to crack down on unapproved regenerative medicine therapies -- though it usually focuses on human products. Those products include various birth tissue products -- such as amniotic fluid or cord blood stem cells -- as well as other stem cell products.

The agency has been attempting to address noncompliant versions of these products since 2021opens in a new tab or window. It now requires manufacturers of such products to meet premarket approval criteria, or conduct research under its investigational new drug requirements.

https://www.medpagetoday.com/special-reports/features/110505

Prolonged Beta-Lactam Dosing Boosts Survival in Sepsis, Septic Shock

 Prolonged infusion of beta-lactam antibiotics for sepsis or septic shock tended to improve mortality compared with conventional intermittent infusion in the BLING III trial, and a meta-analysis including those findings affirmed a significant survival advantage.

The trial narrowly missed its primary endpoint, reducing 90-day all-cause mortality by a relative 9% (24.9% vs 26.8%; OR 0.91, P=0.08), researchers led by Joel M. Dulhunty, MD, PhD, of Royal Brisbane and Women's Hospital in Australia, reported in JAMAopens in a new tab or window and at the Critical Care Reviews meetingopens in a new tab or window in Belfast, Ireland.

The absolute mortality reduction of 1.9%, had a 95% confidence interval ranging from a reduction of 4.9% to an increase of 1.1%, which "includes the possibility of both no important effect and a clinically important benefit in the use of continuous infusions in this group of patients," the group wrote.

The number needed to treat to save one life with prolonged infusion was 50.

Meta-analysis of BLING III together with 17 other randomized trials tipped the scale in favor of a clinically important benefit. Pooled results showed that prolonged infusions reduced 90-day all-cause mortality by a relative 14% (RR 0.86, 95% credible interval [CrI] 0.72-0.98), with a 99.1% posterior probability of superiority.

It also showed high certainty of reduced ICU mortality (RR 0.84, 95% CrI 0.70-0.97) and moderate certainty of an increase in clinical cure (RR 1.16, 95% CrI 1.07-1.31).

"The current evidence presents a high degree of certainty for clinicians to consider prolonged infusions as a standard of care in the management of sepsis and septic shock," concluded Jason A. Roberts, BPharm, PhD, of the UQ Centre for Clinical Research in Brisbane, and colleagues, also in JAMAopens in a new tab or window.

These "major new contributions strengthen the evidence" in support of the Surviving Sepsis Campaign guidelines recommending prolonged infusion of beta-lactams for adults with sepsis or septic shock, which up until now had been only a weak recommendation based on a moderate quality of evidence, according to W. Joost Wiersinga, MD, PhD, MBA, and Michiel van Agtmael, MD, PhD, both of Amsterdam University Medical Center, in an accompanying editorialopens in a new tab or window.

They noted the mechanistic reason for potential advantage: "Most beta-lactams have a half-life of 1 to 2 hours and continuous infusion will improve their pharmacokinetic target. The longer the half-life, the less benefit from continuous infusion."

However, there may be cases where prolonged infusion isn't preferable, they noted. For example, they wrote, "Incompatibility of intravenous comedications with the antibiotic [ceftriaxone] makes administration over a second intravenous entry necessary."

Feasibility and cost-effectiveness are likely in favor of prolonged dosing, since the total daily antibiotic dose is similar and probably less nursing time is needed, the editorialists wrote. "One should be aware that some beta-lactams have a limited pharmaceutical stability. For meropenem, the stability is about 8 hours at room temperature, so it is not suitable for 24-hour infusion, thus affecting bedside logistics."

Importantly, none of the studies included in the meta-analyses showed an increase in toxicity or increase in development of resistance with prolonged dosing, and it might actually be better since low beta-lactam levels at the end of intermittent dosing intervals might increase resistance rates (and failure), Wiersinga and van Agtmael suggested.

BLING (Beta-Lactam Infusion Group) III was conducted in 104 ICUs in Australia, Malaysia, New Zealand, and Europe. It randomized 7,202 critically ill adults age 18 and older (median age 59, 65% male) to open-label treatment with piperacillin-tazobactam or meropenem for sepsis on an equivalent 24-hour dose by either continuous or intermittent (over 30 minutes) infusion for a clinician-determined duration of treatment or until ICU discharge.

The meta-analysis included a total of 18 randomized clinical trials comparing continuous or extended beta-lactam infusion against intermittent infusions in a total of 9,108 critically ill adults with sepsis or septic shock (median age 54, 65% male).

Prespecified subgroup analysis didn't show a difference in all-cause 90-day mortality between treatment groups by antibiotic used (meropenem vs piperacillin-tazobactam), whether the infection was culture positive, kidney replacement therapy status, location of infection (lung vs other), sepsis versus septic shock, or gender. Unlike in some prior reports, the meta-analysis also showed no difference by gram-negative versus gram-positive infection.

"A main challenge for follow-up studies will be to identify subgroups of patients that will benefit most from this treatment option," the editorialists wrote, noting that for "patients with a high renal clearance and infected with a pathogen with a high [minimum inhibitory concentration], increased exposure by continuous infusion could be convincingly superior."

Disclosures

The trial was funded by the National Health and Medical Research Council of Australia, the Belgian Health Care Knowledge Centre, the Health Research Council of New Zealand, the U.K. National Institute for Health and Care Research, the University of Queensland, University Hospital of Nîmes, Skåne University Hospital, and the FDA.

Dulhunty disclosed no relevant relationships with industry. Co-authors reported multiple relationships with industry.

Wiersinga reported receiving grants from Amsterdam University Medical Center and the European Union, performing ad hoc consultancy for AstraZeneca and Shionogi in the field of COVID-19, and serving as a panel member of the Surviving Sepsis Campaign Adult Guidelines and chair of the Dutch Working Party on Antibiotic Policy's Sepsis Guidelines.

Van Agtmael disclosed no relevant relationships.

Primary Source

JAMA

Source Reference: opens in a new tab or windowDulhunty JM, et al "Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis: The BLING III randomized clinical trial" JAMA 2024; DOI: 10.1001/jama.2024.9779.

Secondary Source

JAMA

Source Reference: opens in a new tab or windowAbdul-Aziz MH, et al "Prolonged vs intermittent infusions of β-lactam antibiotics in adults with sepsis or septic shock: A systematic review and meta-analysis" JAMA 2024; DOI: 10.1001/jama.2024.9803.

Additional Source

JAMA

Source Reference: opens in a new tab or windowWiersinga WJ, van Agtmael MA "Resolving the dilemma on continuous vs intermittent β-lactam antibiotics in sepsis" JAMA 2024; DOI: 10.1001/jama.2024.10168.


https://www.medpagetoday.com/criticalcare/sepsis/110607

AstraZeneca's Farxiga approved for type 2 diabetes for children as young as 10

 The FDA has expanded the indication for the drug.

https://seekingalpha.com/news/4115335-astrazeneca-farxiga-approved-type-2-diabetes-children-young-10

Blinken announces more than $400M in new humanitarian aid for Palestinians in Gaza

 US Secretary of State Antony Blinken on Tuesday announced more than $400 million in new humanitarian aid for Palestinians in Gaza as he again called on Hamas to accept a ceasefire proposal that he described as the most effective way to address the humanitarian devastation.

The top US diplomat, speaking at an emergency humanitarian aid conference in Jordan, also called on nations to give more aid to support those in the war-torn strip.

The humanitarian situation on the ground in Gaza has become catastrophic over the eight months of Israel’s war against Hamas. The Israeli government has restricted access and items that have been able to make their way into the strip. Humanitarian aid organizations have had to contend with a destroyed infrastructure inhibiting their ability to deliver the critically-needed aid, and aid workers have been caught in the crossfire.

“The crisis in Gaza is immense,” Blinken acknowledged.

“Only one third of the current United Nations appeal is funded. That leaves a shortfall of approximately $2 billion to $3 billion. Every country can help fill this gap. Yet some who expressed great concern over the suffering of the Palestinian people in Gaza, including countries with the capacity to give a lot, have provided very little – or nothing at all,” Blinken said without naming specific countries. “It is time for everyone, everyone, to step up.”

The new $404 million in funding from the US will go toward “food, safe drinking water, health care, protection, education, shelter, and psychosocial support,” according to a media note from the State Department.

In his remarks Tuesday, Blinken said that “particularly in recent months, Israel has taken some important steps to open more crossings, to address obstacles to the delivery of assistance, but it can and must do more.”

“As we conveyed directly to the Israeli government, it is crucial to speed up the inspection trucks and reduce backlogs, to provide greater clarity on and shorten the list of prohibited goods, to increase visas for aid workers and to process them more quickly, to create clearer, more effective channels for humanitarian groups to deconflict with IDF operations, to surge life-saving medicine and equipment, to provide everything necessary to repair water and sanitation systems,” he said.

“And Israel must take further steps to reduce civilian casualties, even as it confronts an enemy that started this war with the barbaric slaughter of civilians on October 7,” Blinken said.

Despite Blinken’s claims about the “important steps” taken by the Israeli government, humanitarian workers say that the situation on the ground has only worsened, particularly as the Israeli military has stepped up operations in Rafah, where millions of Palestinians previously fled. Blinken himself acknowledged in his remarks Tuesday that “more than a million people have been displaced from Rafah alone, in the last month alone – many of whom had already been uprooted multiple times.”

“The situation is back to one of the lowest points, which is quite shocking at this point,” said Arnaud Quemin, the Middle East director at Mercy Corps.

There was an “ecosystem” for humanitarian aid work in Rafah – some non-governmental organizations and UN agencies provide logistical facilities, others provide transportation, “everybody works together to make that possible,” he described to CNN. But with the Israeli military operation happening since the beginning of May, “it could not function anymore, it just ground to a halt.”

International officials and humanitarian workers have described the situation in Gaza as unprecedented in its complexity and scope. UN Secretary-General Antonio Guterres said at the conference Tuesday that “the speed and scale of the carnage and killing in Gaza is beyond anything in my years as Secretary-General.”

The top US diplomat in his remarks stressed that the US sees Hamas as the sole obstacle to a ceasefire that would alleviate the humanitarian suffering.

“Today, as we gather, one, and only one, thing stands in the way of the deal happening, and that’s Hamas,” he said. “So my primary and first message today to every government, to every multilateral institution, to every humanitarian organization that wants to relieve the massive suffering in Gaza: get Hamas to take the deal.”

Others also emphasized the need for a ceasefire in order to enable humanitarian work.

“The status quo cannot hold. Without a political agreement supporting a ceasefire, the humanitarian assistance system is pushed to a point of collapse,” said Mirjana Spoljaric, the president of the International Committee of the Red Cross, at the conference on Tuesday.

https://www.cnn.com/2024/06/11/politics/antony-blinken-gaza-aid-humanitarian/index.html